Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Aug 6, 2021 → Jun 13, 2023
NCT ID
NCT04883528About Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo
Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo is a phase 1/2 stage product being developed by Novartis for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04883528. Target conditions include Covid19.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04883528 | Phase 1/2 | Completed |
Competing Products
20 competing products in Covid19